 |
PDF »
February 2, 2006
Cougar Biotechnology Announces Approval of IND for Abiraterone Acetate
Los Angeles, CA, February 2, 2006 - Cougar Biotechnology, Inc, a privately held biotechnology company, today announced that its Investigational New Drug (IND) application for the Company's drug CB7630 (abiraterone acetate) has been approved by the U.S. Food and Drug Administration (FDA). This will allow Cougar to conduct a Phase I clinical trial of CB7630, an orally active inhibitor of the steroidal enzyme 17alpha-hydroxylase/C17,20 lyase, for the treatment of advanced prostate cancer in the United States.
The Phase I trial of CB7630 will be conducted at the University of California San Francisco Comprehensive Cancer Center with Charles J. Ryan, MD, as the principal investigator of the trial. "Due to the limited number of treatment options for patients that fail first line hormonal therapy, we are very eager to investigate CB7630 (abiraterone acetate) as a potential second line hormonal therapy" said Dr. Ryan. "CB7630 represents a novel drug with a unique mechanism of action that could confer clinical benefit to hormone refractory prostate cancer patients."
Dr. Arie Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology said, "This is an important milestone for the Company and for CB7630. We look forward to initiating the Phase I clinical trial of CB7630 in the U.S., which complements the Phase I trial that we initiated late last year in the United Kingdom." Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added "Approval of the IND for CB7630 was a key corporate objective for the Company this year. We look forward to initiating the Phase I trial of CB7630 in the coming months."
About Cougar Biotechnology
Cougar Biotechnology, Inc. is a Los Angeles-based private biotechnology company established to in-license and develop clinical stage drugs, with a specific focus on the field of oncology. Cougar's oncology portfolio includes CB7630, which is currently being tested in a Phase I clinical trial in prostate cancer, CB3304, which is currently in a Phase I trial in non-Hodgkin's lymphoma and CB1089, which has been clinically tested in a number of solid tumor types.
Further information about Cougar Biotechnology can be found at www.cougarbiotechnology.com.
Contact
Alan H. Auerbach
Cougar Biotechnology, Inc.
+1 310 443 4209
ahauerbach@cougarbiotechnology.com
Notes: The Institute of Cancer Research 1. The Institute of Cancer Research is Europe's leading cancer research centre with expert scientists working on cutting edge research. It was founded in 1909 to carry out research into the causes of cancer and to develop new strategies for its prevention, diagnosis, treatment and care. For more information please visit www.icr.ac.uk 2. The Institute works in a unique partnership with The Royal Marsden NHS Foundation Trust, forming the largest comprehensive cancer centre in Europe. This relationship enables close daily contact with those on the frontline in the fight against cancer - the clinicians, the carers and most importantly, the patients.
| | |
Cougar Biotechnology, Inc.
10990 Wilshire Blvd, Suite 1200
Los Angeles, CA 90024
(310) 943-8040 Main
(310) 943-8059 Fax |
